Sukhes Mukherjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sukhes Mukherjee has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Suman Kumar Ray
25 shared publications- Suman Kumar Ray
Independent Researcher, Bhopal, Madhya Pradesh, 462020, India
23 shared publications Neha Masarkar
Department of Biochemistry, All India Institute of Medical Sciences, Bhopal Saket Nagar, Bhopal, Madhya Pradesh – 462020, India
7 shared publicationsSakshi Rai
Department of Biochemistry , All India Institute of Medical Sciences , Bhopal , Madhya Pradesh , India
4 shared publicationsJagat R. Kanwar
Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, India
3 shared publicationsAlakesh Bisai
Indian Institute of Science Education and Research Kolkata, Nadia, India
2 shared publications
Latest Publications
- 20 January 2026
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 55 (6) , 2485-2498
Bio-reductive hetero-bimetallic Co(iii)–Pt(ii) complex for tumor-selective platinum release and cytotoxicity
The bio-reductive [Co(iii)–Pt(ii)] complex is developed for the selective release of Pt( ii ) by exploiting tumor-specific redox conditions for selective anticancer activity.
- 20 January 2026
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 55 (6) , 2485-2498
Bio-reductive hetero-bimetallic Co(iii)–Pt(ii) complex for tumor-selective platinum release and cytotoxicity
The bio-reductive [Co(iii)–Pt(ii)] complex is developed for the selective release of Pt( ii ) by exploiting tumor-specific redox conditions for selective anticancer activity.
- Open Access
- 29 December 2025
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 23 (1) , 71-85
In silico evaluation of bioactive compounds as potential inhibitors targeting HIF-1α/VEGFA/BACE1 pathway against Alzheimer’s disease
Objectives: Neurodegenerative disorders such as Alzheimer’s disease (AD) are characterized by progressive neuronal degeneration, predominantly caused by the accumulation of amyloid-beta (Aβ) and neuroinflammatory processes. Hypoxia, characterized by diminished oxygen levels, intensifies these mechanisms by stimulating hypoxiainducible factor 1-alpha (HIF-1α), potentially enhancing BACE1 enzyme activity and resulting in increased Aβ synthesis and render neurons especially susceptible to hypoxia, exacerbating disease progression. Existing therapies are constrained by inadequate medication distribution across the blood-brain barrier and associated adverse effects. This study aims to identify potential therapeutic agents targeting HIF-1α, VEGFA, BACE1 key molecules involved in AD by exploring neuroprotective effects of bioactive compounds like benzyl isothiocyanate (BITC), Aurantiamide Acetate (AA), and galantamine, with the goal of developing more effective, targeted treatments. Methods: We used in silico screening, such as molecular docking and ADMET analysis, to assess the binding affinity, pharmacokinetics, and toxicity of potential inhibitors, followed by in vitro testing. Results: Results identified several compounds with strong binding affinities and favorable ADMET profiles as potential inhibitors of HIF-1α, VEGFA, BACE1 and experimental data support that hypoxia, via HIF-1α, upregulates BACE1, increasing Aβ production and contributing to AD. Targeting these pathways may offer a multi-faceted approach to therapy, reducing neuroinflammation and amyloid pathology. Conclusions: In silico screening of potential molecules across different pathogenic pathways in Alzheimer’s disease shows promise in developing successful therapeutic methods and continued validation may result in more tailored and safer medicines that address underlying neurodegenerative pathways.
- 29 December 2025
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
- Vol. 23 (1) , 71-85
Open AccessIn silico evaluation of bioactive compounds as potential inhibitors targeting HIF-1α/VEGFA/BACE1 pathway against Alzheimer’s disease
Objectives: Neurodegenerative disorders such as Alzheimer’s disease (AD) are characterized by progressive neuronal degeneration, predominantly caused by the accumulation of amyloid-beta (Aβ) and neuroinflammatory processes. Hypoxia, characterized by diminished oxygen levels, intensifies these mechanisms by stimulating hypoxiainducible factor 1-alpha (HIF-1α), potentially enhancing BACE1 enzyme activity and resulting in increased Aβ synthesis and render neurons especially susceptible to hypoxia, exacerbating disease progression. Existing therapies are constrained by inadequate medication distribution across the blood-brain barrier and associated adverse effects. This study aims to identify potential therapeutic agents targeting HIF-1α, VEGFA, BACE1 key molecules involved in AD by exploring neuroprotective effects of bioactive compounds like benzyl isothiocyanate (BITC), Aurantiamide Acetate (AA), and galantamine, with the goal of developing more effective, targeted treatments. Methods: We used in silico screening, such as molecular docking and ADMET analysis, to assess the binding affinity, pharmacokinetics, and toxicity of potential inhibitors, followed by in vitro testing. Results: Results identified several compounds with strong binding affinities and favorable ADMET profiles as potential inhibitors of HIF-1α, VEGFA, BACE1 and experimental data support that hypoxia, via HIF-1α, upregulates BACE1, increasing Aβ production and contributing to AD. Targeting these pathways may offer a multi-faceted approach to therapy, reducing neuroinflammation and amyloid pathology. Conclusions: In silico screening of potential molecules across different pathogenic pathways in Alzheimer’s disease shows promise in developing successful therapeutic methods and continued validation may result in more tailored and safer medicines that address underlying neurodegenerative pathways.
- Open Access
- 5 December 2025
- Vol. 36 (4) , 499-515
Evaluation of Adropin, Irisin and Cytokeratin 18 as Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comparative Clinical Study.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become the leading cause of chronic liver disease globally, affects more than one-third of the adult population and includes a spectrum of conditions ranging from simple steatosis of liver to metabolic dysfunction-associated steatohepatitis (MASH), progressive fibrosis, cirrhosis and, in some cases, hepatocellular carcinoma. Early detection and accurate staging are important to prevent disease progression and studies have recently identified metabolic and apoptotic markers such as Adropin, a peptide hormone secreted by the liver that is involved in energy homeostasis; Irisin, a myokine that is linked to exercise and metabolic regulation; and CK-18, a biomarker of hepatocyte apoptosis.Methods: Using FibroScan for the diagnosis and staging of MASLD, CAP scores were used for steatosis and liver stiffness measurements for fibrosis. Quantification of serum adropin, irisin, and CK-18 was done, and independent t-tests, correlation analysis, and ROC curve analysis were used for statistical analysis to assess the diagnostic potential. Adropin levels were lower in MASLD cases than in controls and decreased further with the severity of the disease. The association was highly significant (p < 0.001), indicating a very high negative correlation between Adropin levels and hepatic dysfunction. Levels of CK-18 were greatly increased in MASLD patients and were highly positively correlated with the degrees of fibrosis and steatosis (p < 0.001), which supports the hypothesis that it is a marker of hepatocyte apoptosis. The significant changes in their levels observed in MASLD patients suggest their possible application in multimarker diagnostic strategies. Nonetheless, the inconsistent behavior of Irisin in this study requires more conclusive evidence from future studies involving larger samples. Such biomarkers may help in identifying the disease at an early stage and improve the management of the disease.
- 5 December 2025
- Vol. 36 (4) , 499-515
Open AccessEvaluation of Adropin, Irisin and Cytokeratin 18 as Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comparative Clinical Study.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become the leading cause of chronic liver disease globally, affects more than one-third of the adult population and includes a spectrum of conditions ranging from simple steatosis of liver to metabolic dysfunction-associated steatohepatitis (MASH), progressive fibrosis, cirrhosis and, in some cases, hepatocellular carcinoma. Early detection and accurate staging are important to prevent disease progression and studies have recently identified metabolic and apoptotic markers such as Adropin, a peptide hormone secreted by the liver that is involved in energy homeostasis; Irisin, a myokine that is linked to exercise and metabolic regulation; and CK-18, a biomarker of hepatocyte apoptosis.Methods: Using FibroScan for the diagnosis and staging of MASLD, CAP scores were used for steatosis and liver stiffness measurements for fibrosis. Quantification of serum adropin, irisin, and CK-18 was done, and independent t-tests, correlation analysis, and ROC curve analysis were used for statistical analysis to assess the diagnostic potential. Adropin levels were lower in MASLD cases than in controls and decreased further with the severity of the disease. The association was highly significant (p < 0.001), indicating a very high negative correlation between Adropin levels and hepatic dysfunction. Levels of CK-18 were greatly increased in MASLD patients and were highly positively correlated with the degrees of fibrosis and steatosis (p < 0.001), which supports the hypothesis that it is a marker of hepatocyte apoptosis. The significant changes in their levels observed in MASLD patients suggest their possible application in multimarker diagnostic strategies. Nonetheless, the inconsistent behavior of Irisin in this study requires more conclusive evidence from future studies involving larger samples. Such biomarkers may help in identifying the disease at an early stage and improve the management of the disease.
- Open Access
- 5 December 2025
- Vol. 36 (4) , 429-442
Assessing the Impact of Arm Rotation with Walking Exercise on Blood Glucose and HbA1c Levels in Patients with Diabetes Mellitus: A Hospital Based Study.
Effective management of blood glucose levels is crucial for individuals with diabetes mellitus, and incorporating physical activity plays a vital role. Recent studies suggest that combining simple, low-impact exercises such as arm rotation and walking can enhance postprandial glycemic control. This study aims to evaluate the impact of a combined arm rotation and walking exercise regimen on postprandial blood glucose and HbA1c levels in people with type 2 diabetes. A randomized controlled trial was conducted with 92 participants diagnosed with type 2 diabetes, aged 18-82 years. Participants were randomly assigned to an intervention group, which performed a structured exercise protocol involving arm rotation and walking, or a control group, which maintained usual activity. The intervention lasted for 24 weeks, with sessions held five times per week. Blood samples were collected at baseline and after the intervention to measure fasting blood glucose, postprandial blood glucose, and HbA1c levels. Data were analysed using paired t-tests and ANOVA to compare pre-and post-intervention results. The intervention group showed a significant reduction in postprandial blood glucose levels (mean decrease of 25 mg/dL, p < 0.01) and HbA1c levels (mean decrease of 0.5%, p < 0.05) after 24 weeks. In contrast, the control group exhibited no significant changes. Adherence to the exercise regimen was high, and no adverse events were reported, indicating good tolerability. The findings suggest that combining arm rotation with walking exercises is an effective and practical approach to improve glycemic control in individuals with type 2 diabetes. The improvements may be attributed to enhanced insulin sensitivity and increased muscle activity. These results support incorporating simple, accessible exercises into daily routines for better diabetes management. Further research is needed to assess long-term benefits and optimal exercise protocols.
- 5 December 2025
- Vol. 36 (4) , 429-442
Open AccessAssessing the Impact of Arm Rotation with Walking Exercise on Blood Glucose and HbA1c Levels in Patients with Diabetes Mellitus: A Hospital Based Study.
Effective management of blood glucose levels is crucial for individuals with diabetes mellitus, and incorporating physical activity plays a vital role. Recent studies suggest that combining simple, low-impact exercises such as arm rotation and walking can enhance postprandial glycemic control. This study aims to evaluate the impact of a combined arm rotation and walking exercise regimen on postprandial blood glucose and HbA1c levels in people with type 2 diabetes. A randomized controlled trial was conducted with 92 participants diagnosed with type 2 diabetes, aged 18-82 years. Participants were randomly assigned to an intervention group, which performed a structured exercise protocol involving arm rotation and walking, or a control group, which maintained usual activity. The intervention lasted for 24 weeks, with sessions held five times per week. Blood samples were collected at baseline and after the intervention to measure fasting blood glucose, postprandial blood glucose, and HbA1c levels. Data were analysed using paired t-tests and ANOVA to compare pre-and post-intervention results. The intervention group showed a significant reduction in postprandial blood glucose levels (mean decrease of 25 mg/dL, p < 0.01) and HbA1c levels (mean decrease of 0.5%, p < 0.05) after 24 weeks. In contrast, the control group exhibited no significant changes. Adherence to the exercise regimen was high, and no adverse events were reported, indicating good tolerability. The findings suggest that combining arm rotation with walking exercises is an effective and practical approach to improve glycemic control in individuals with type 2 diabetes. The improvements may be attributed to enhanced insulin sensitivity and increased muscle activity. These results support incorporating simple, accessible exercises into daily routines for better diabetes management. Further research is needed to assess long-term benefits and optimal exercise protocols.
- Open Access
- 22 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-22
Pharmacokinetic, docking, and DFT analyses reveal Moringa oleifera phytochemicals as inhibitors of HIF-1α/VEGF/GLUT1 signaling pathway in breast cancer
Breast cancer is among the most heterogeneous and aggressive malignancies. Hypoxia-driven activation of Hypoxia-inducible factor-1 alpha (HIF-1α) in breast cancers triggers the transcription of a battery of genes that facilitate tumor progression and result in poor prognosis. Based on the reported anti-cancer properties of Moringa oleifera (Mo), this study explores the therapeutic effects of isolated bioactive compounds from Mo, namely Aurantiamide Acetate (AA) and Benzyl Isothiocyanate (BITC), on HIF-1α-regulated key genes- vascular endothelial growth factor (VEGF) and glucose transporter 1 (GLUT1), targeting the HIF-1α/VEGF/GLUT1 axis, which is central to angiogenesis and metabolic adaptation in tumors using a comprehensive in silico approach. The X-ray crystallographic structures of HIF-1α, VEGF, and GLUT1 were retrieved from PDB and employed as receptor targets for molecular docking studies against 3D conformers of AA and BITC using AutoDock Vina to evaluate their binding affinity and interaction profiles. Post-docking conformational analyses were conducted utilizing Discovery Studio. The pharmacological relevance of the compounds was assessed using SwissADME, ADMETSaR, and ADMETlab3.0 web servers for drug-likeness, oral bioavailability, and ADMET profiles. Subsequently, robust molecular dynamics simulations were executed for 500 nanoseconds using the Desmond module (Schrödinger v2019) to evaluate the structural stability of the ligand–receptor complexes under physiologically mimetic conditions. Additionally, Density Functional Theory (DFT) calculations were performed using Gaussian 09 software to probe the electronic properties, reactivity descriptors, and frontier molecular orbitals of the ligands. Docking outcomes revealed strong binding affinities of protein-ligand complexes, mediated by hydrogen bonding and hydrophobic interactions, further corroborated by consistent pharmacokinetic profiles and low toxicity. MDS trajectories revealed structural convergence and stability across all complexes, as indicated by RMSD, RMSF, SASA, and radius of gyration (rGyr) analyses. Overall, the integrated in silico approach highlights the promising therapeutic potential of these phytocompounds as natural, bioavailable, and mechanistically rational inhibitors of hypoxia-associated targets in breast cancer.
- 22 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-22
Open AccessPharmacokinetic, docking, and DFT analyses reveal Moringa oleifera phytochemicals as inhibitors of HIF-1α/VEGF/GLUT1 signaling pathway in breast cancer
Breast cancer is among the most heterogeneous and aggressive malignancies. Hypoxia-driven activation of Hypoxia-inducible factor-1 alpha (HIF-1α) in breast cancers triggers the transcription of a battery of genes that facilitate tumor progression and result in poor prognosis. Based on the reported anti-cancer properties of Moringa oleifera (Mo), this study explores the therapeutic effects of isolated bioactive compounds from Mo, namely Aurantiamide Acetate (AA) and Benzyl Isothiocyanate (BITC), on HIF-1α-regulated key genes- vascular endothelial growth factor (VEGF) and glucose transporter 1 (GLUT1), targeting the HIF-1α/VEGF/GLUT1 axis, which is central to angiogenesis and metabolic adaptation in tumors using a comprehensive in silico approach. The X-ray crystallographic structures of HIF-1α, VEGF, and GLUT1 were retrieved from PDB and employed as receptor targets for molecular docking studies against 3D conformers of AA and BITC using AutoDock Vina to evaluate their binding affinity and interaction profiles. Post-docking conformational analyses were conducted utilizing Discovery Studio. The pharmacological relevance of the compounds was assessed using SwissADME, ADMETSaR, and ADMETlab3.0 web servers for drug-likeness, oral bioavailability, and ADMET profiles. Subsequently, robust molecular dynamics simulations were executed for 500 nanoseconds using the Desmond module (Schrödinger v2019) to evaluate the structural stability of the ligand–receptor complexes under physiologically mimetic conditions. Additionally, Density Functional Theory (DFT) calculations were performed using Gaussian 09 software to probe the electronic properties, reactivity descriptors, and frontier molecular orbitals of the ligands. Docking outcomes revealed strong binding affinities of protein-ligand complexes, mediated by hydrogen bonding and hydrophobic interactions, further corroborated by consistent pharmacokinetic profiles and low toxicity. MDS trajectories revealed structural convergence and stability across all complexes, as indicated by RMSD, RMSF, SASA, and radius of gyration (rGyr) analyses. Overall, the integrated in silico approach highlights the promising therapeutic potential of these phytocompounds as natural, bioavailable, and mechanistically rational inhibitors of hypoxia-associated targets in breast cancer.
- 2 September 2025
- Published by Elsevier in Neuroscience
- Vol. 585, 233-248
Advancing nanotheranostics for neuro-immunological disorders: current status and future prospects
- 2 September 2025
- Published by Elsevier in Neuroscience
- Vol. 585, 233-248
Advancing nanotheranostics for neuro-immunological disorders: current status and future prospects
- 2 September 2025
- Published by Elsevier in Cancer Genetics
- Vol. 298-299, 78-87
Exploring replication stress and cellular senescence as key targets in novel cancer therapies
- 2 September 2025
- Published by Elsevier in Cancer Genetics
- Vol. 298-299, 78-87
Exploring replication stress and cellular senescence as key targets in novel cancer therapies
- 7 August 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (11) , 5382-5394
Bio-reductive Co( iii )–doxorubicin complex for cancer cell-selective delivery of doxorubicin and potent anticancer activity
We report a novel Co( iii )–doxorubicin complex as a novel bio-reductive prodrug, offering a more effective and safer alternative for cancer therapy.
- 7 August 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (11) , 5382-5394
Bio-reductive Co( iii )–doxorubicin complex for cancer cell-selective delivery of doxorubicin and potent anticancer activity
We report a novel Co( iii )–doxorubicin complex as a novel bio-reductive prodrug, offering a more effective and safer alternative for cancer therapy.
- 19 May 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 771, 152048
Mechanical factors in the breast cancer microenvironment: Emphasizing functional adaptation
- 19 May 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 771, 152048
Mechanical factors in the breast cancer microenvironment: Emphasizing functional adaptation